Pertussis vaccines: acellular versus whole-cell. 1996

C R Boughton
Department of Infectious Diseases, Prince Henry Hospital, Sydney, NSW.

Acellular pertussis vaccines containing purified Bordetella pertussis antigens have now been extensively field tested. They produce a significantly lower rate of reactions than whole-cell vaccines and their efficacy is either comparable or superior. At least three antigens appear necessary for good protection: pertussis toxoid, filamentous haemagglutinin and pertactin (an outer-membrane protein); fimbrial agglutinogens are probably not needed. It is hoped that a cellular pertussis vaccine will soon be licensed in Australia for both primary and booster vaccination.

UI MeSH Term Description Entries
D010567 Pertussis Vaccine A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed) Vaccine, Pertussis
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014917 Whooping Cough A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath. Pertussis,Bordetella pertussis Infection, Respiratory,Cough, Whooping,Pertusses
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

C R Boughton
March 1992, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses,
C R Boughton
January 1994, The Annals of pharmacotherapy,
C R Boughton
June 1987, Lancet (London, England),
C R Boughton
October 2015, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia,
C R Boughton
June 2016, Expert review of vaccines,
C R Boughton
February 2013, The New England journal of medicine,
C R Boughton
March 2000, BMJ (Clinical research ed.),
Copied contents to your clipboard!